CVS Caremark will implement targeted updates to its most common commercial template formularies on July 1.

Workers value tailored guidance that aligns with their personal goals, reassures them and builds their confidence, UBS reports.

Fifty-four percent of workers would give up at least one workplace perk for employer-covered GLP-1 treatment.

For employers' health plans, the new ATTR-CM specialty drugs could cost $500,000 per participant treated.